Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience

Area of Science:

• Immunology
• Vaccinology
• Global Health

Background:

• The global HIV/AIDS pandemic necessitates urgent vaccine development due to socio-economic impacts, particularly in developing countries.
• Over two decades of research have yielded limited success, highlighting the need for collaborative efforts and innovative approaches.
• Limited pharmaceutical industry investment in HIV/AIDS vaccine research underscores the importance of public-funded initiatives and international partnerships.

Purpose of the Study:

• To review the establishment and scientific strategy of the AIDS Vaccine Integrated Project (AVIP) consortium.
• To highlight AVIP's role in accelerating the development of novel HIV/AIDS vaccine candidates.
• To showcase AVIP as a model for international collaboration in vaccine research and development.

Main Methods:

• AVIP is a European Commission-funded, consortium-based program involving international experts from the European Union and developing countries.
• The program focuses on developing novel combined vaccines incorporating both regulatory and structural HIV antigens.
• These combined vaccines leverage antigens previously tested individually in Phase I clinical trials.

Main Results:

• AVIP aims to fast-track new HIV/AIDS vaccine candidates for Phase I clinical trials in Europe, with potential advancement to Phase II/III trials in developing countries.
• Combined vaccines targeting both regulatory (early) and structural (late) HIV antigens are hypothesized to be superior to single-component vaccines.
• The strategy exploits the immunomodulatory functions of HIV regulatory proteins to enhance immunity against structural vaccine components.

Conclusions:

• International collaborative networks, like the AVIP consortium, are essential for efficient HIV/AIDS vaccine development.
• The AVIP model demonstrates a synergistic approach to optimizing research and funding for HIV/AIDS vaccine candidates.
• Combined antigen strategies represent a promising rational design for next-generation HIV/AIDS vaccines.